

Relapsed/refractory patients

## Top-line results from the phase II study of CLR 131 – CLOVER-1



Emily Smith | Feb 28, 2019

CLR 131 is a radioiodinated phospholipid ether-drug conjugate that utilizes malignant cells selective uptake and retention of phospholipid ethers. The use of CLR 131 is being investigated in the CLOVER-1 study in patients with relapsed/refractory (RR) B-cell hematologic cancers including multiple myeloma (MM). CLOVER-1 is an open-label, multicentre, phase II study. The top-line results from the study in patients with RRMM have been announced and are provided here.<sup>1</sup>

### Background on the study ([NCT02952508](#))<sup>1,2</sup>

- CLR 131 is being investigated in multiple B-cell hematologic cancers
- Enrolled patients with RRMM must have received at least 2 prior regimens including 1 proteasome inhibitor and 1 immunomodulatory agent
- Primary endpoints:
  - Clinical benefit response
  - Overall response rate (ORR)
  - Progression-free survival
  - Median overall survival
- Dose: 15.625 mCi/m<sup>2</sup> administered intravenously on days 1 and 8
  - Determined based on phase I results of cohort 5 (patients with RRMM)
- Patients also receive 40mg oral dexamethasone weekly for up to 12 weeks

### Phase II top-line results<sup>1</sup>

- Patients received a dose of 25 mCi/m<sup>2</sup> of CLR 131, administered as a single 30-minute infusion on days 1 and 8
- Median number of prior lines of therapy: 5
- Efficacy:
  - ORR (N = 10): 30%
  - Very good partial response: N = 1
  - Partial response: N = 2

The pharmaceutical company responsible for the trial continue to dose patients at higher fractionated doses with data from other cohorts expected to be announced later this year.

**References**

1. Collectar Reports Positive Top-line Response Rate of 30% from R/R Multiple Myeloma Cohort in Ongoing Phase 2 Study of CLR 131. <https://globenewswire.com/news-release/2019/02/25/1741555/0/en/Collectar-Reports-Positive-Top-line-Response-Rate-of-30-from-R-R-Multiple-Myeloma-Cohort-in-Ongoing-Phase-2-Study-of-CLR-131.html> [accessed 2019 Feb 26]
2. Study of CLR 131 in Relapsed or Refractory Select B-Cell Malignancies (CLOVER-1). <https://clinicaltrials.gov/ct2/show/NCT02952508> [accessed 2019 Feb 26]

---

© 2019 Scientific Education Support Ltd. This PDF is provided for personal use only. For wider or commercial use, please seek permission from [secretariat@scientificeducationsupport.com](mailto:secretariat@scientificeducationsupport.com) and attribute the source as: <<https://multiplemyelomahub.com/medical-information/top-line-results-from-the-phase-ii-study-of-clr-131-clover-1>>